Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
Emily M. Hsieh, Regina M. Myers, Bonnie Yates, Colleen Annesley, Samuel John, Agne Taraseviciute, Seth M. Steinberg, Jennifer Sheppard, Perry Chung, Lee Chen, Daniel W. Lee, Amanda M. DiNofia, Stephan A. Grupp, Michael R. Verneris, Theodore W. Laetsch, Deepa Bhojwani, Patrick A. Brown, Michael A. Pulsipher, Susan R. Rheingold, Rebecca Gardner, Lia Gore, Nirali N. Shah, Adam J. Lamble
Abstract
2] he cumulative incidence of SMNs continues to increase as more childhood cancer survivors reach adulthood. 2 Among survivors of childhood acute lymphoblastic leukemia (ALL), those with relapsed disease and/or those requiring HSCT have the highest 20-year cumulative incidence of SMNs at 4.2%. 6 There is a paucity of literature regarding how cellular immune-based therapies influence the risk of SMNs.